Submit Your Multiple Sclerosis Research to a Journal That Understands Your Field
Join leading neurologists, immunologists, and MS researchers publishing breakthrough discoveries in demyelinating diseases, neuroinflammation, and patient care
We Specialize in Multiple Sclerosis and Related Neurological Disorders
Our editorial board comprises leading experts in MS pathophysiology, neuroimmunology, and clinical neurology. We understand the complexities of demyelinating diseases and provide expert peer review from specialists who speak your scientific language.
Two Convenient Ways to Submit Your Manuscript
Choose the submission method that works best for your research workflow. Both options provide secure, efficient manuscript handling with full tracking capabilities.
ManuscriptZone Portal
Our comprehensive manuscript management system designed for complex submissions with multiple authors, extensive supplementary materials, and detailed tracking needs.
- Auto-save functionality prevents data loss
- Real-time submission status tracking
- Direct access to reviewer comments and editor decisions
- Guided workflow with step-by-step instructions
- Secure file upload for manuscripts, figures, and supplementary data
- Revision management with version control
- Email notifications at every stage
Quick Submission Form
Streamlined submission process ideal for straightforward manuscripts, case reports, or when you need to submit quickly without creating an account.
- No account registration required
- Single-page submission form
- Perfect for case reports and short communications
- Immediate confirmation email
- Faster initial processing
- Ideal for time-sensitive submissions
Manuscript Types We Publish
We welcome diverse contributions to MS research, from basic science discoveries to clinical trials and patient-centered outcomes. Each manuscript type undergoes rigorous peer review by specialists in your specific area of MS research.
Original Research Articles
Novel findings in MS pathophysiology, immunology, genetics, neuroimaging, or therapeutic interventions. Include mechanistic studies, biomarker discovery, and translational research.
Clinical Trials
Randomized controlled trials, observational studies, and phase I-IV trials of disease-modifying therapies, symptomatic treatments, or rehabilitation interventions. CONSORT compliance required.
Systematic Reviews & Meta-Analyses
Comprehensive evidence synthesis on MS diagnosis, treatment efficacy, prognostic factors, or disease mechanisms. PRISMA guidelines required for systematic reviews.
Case Reports
Unusual presentations of MS, rare variants (tumefactive MS, Marburg variant), atypical responses to therapy, or novel diagnostic challenges. Include detailed clinical, imaging, and laboratory data.
Neuroimaging Studies
Advanced MRI techniques (DTI, MTR, fMRI), OCT findings, PET imaging, or novel imaging biomarkers for disease activity, progression, or treatment response monitoring.
Immunology & Pathophysiology
Mechanistic studies of autoimmunity, T-cell and B-cell responses, cytokine profiles, blood-brain barrier dysfunction, or molecular pathways in demyelination and neurodegeneration.
Biomarker Discovery
Novel serum, CSF, or imaging biomarkers for MS diagnosis, disease activity monitoring, treatment response prediction, or prognosis. Include validation cohorts when possible.
Quality of Life & Patient-Reported Outcomes
Studies on fatigue, cognitive impairment, depression, employment, caregiver burden, or validated outcome measures. Include psychometric validation when introducing new instruments.
Therapeutic Advances
Real-world evidence studies, long-term safety data, comparative effectiveness research, or novel therapeutic approaches including stem cell therapy, remyelination strategies, or neuroprotection.
Epidemiology & Public Health
Prevalence and incidence studies, geographic distribution patterns, environmental risk factors, genetic epidemiology, or healthcare utilization and cost-effectiveness analyses.
Pediatric MS & Related Disorders
Studies specific to pediatric-onset MS, ADEM, or other childhood demyelinating syndromes. Include age-appropriate outcome measures and developmental considerations.
Short Communications
Preliminary findings, novel methodologies, or timely observations that warrant rapid dissemination. Ideal for hypothesis-generating data or technical innovations.
Pre-Submission Checklist
Ensure your manuscript is complete and ready for submission. A complete submission accelerates the review process and increases your chances of acceptance.
- Manuscript File: Word (.docx) or LaTeX format, double-spaced, line numbers enabled, all sections complete (Abstract, Introduction, Methods, Results, Discussion, Conclusions)
- Figures and Tables: High-resolution figures (minimum 300 DPI, TIFF or EPS format), editable tables, all properly numbered and cited in text
- Ethics Documentation: IRB/Ethics committee approval letter, patient consent forms for case reports, animal care committee approval (if applicable)
- Clinical Trial Registration: Trial registration number (ClinicalTrials.gov, EudraCT, etc.) for all interventional studies
- Author Information: Complete names, affiliations, ORCID IDs, and email addresses for all authors; corresponding author clearly designated
- Competing Interests: Declaration of financial relationships, consulting fees, speaker honoraria, or other potential conflicts related to MS therapies or diagnostics
- Funding Statement: All funding sources acknowledged, grant numbers provided
- Data Availability: Statement on data sharing, repository links if applicable (required for clinical trials)
- References: Formatted according to journal style, all citations verified, DOIs included where available
- Cover Letter: Addressed to the Editor-in-Chief, explaining significance to MS field, confirming originality and author agreement
Transparent Peer Review Process
We believe in transparency. Here's exactly what happens to your manuscript from submission to publication, with realistic timelines based on our actual performance data.
Submission Received
Your manuscript enters our system. You receive immediate confirmation with a unique manuscript ID for tracking.
Day 0Editorial Screening
Editor-in-Chief or Associate Editor reviews for scope fit, scientific merit, and completeness. Plagiarism check performed using iThenticate (similarity must be under 30%).
Days 1-3Reviewer Assignment
Manuscript assigned to 2-3 expert reviewers with specific expertise in your MS research area (e.g., neuroimaging specialists for MRI studies, immunologists for mechanistic work).
Days 4-7Peer Review
Reviewers evaluate scientific rigor, methodology, statistical analysis, clinical relevance, and contribution to MS field. Single-blind review ensures unbiased assessment.
Days 8-21Editorial Decision
Editor synthesizes reviewer comments and makes decision: Accept, Minor Revisions, Major Revisions, or Reject. You receive detailed feedback regardless of outcome.
Days 22-28Revision Submission
If revisions requested, you submit revised manuscript with point-by-point response to reviewers. Most authors complete revisions within 30 days.
Days 29-58Re-Review
Revised manuscript sent back to original reviewers to verify that concerns were adequately addressed. Faster than initial review.
Days 59-72Final Acceptance
Manuscript accepted for publication. You receive acceptance letter and copyright transfer agreement. APC invoice sent (waivers available for eligible authors).
Day 73Production & Publication
Copyediting, typesetting, and final proofing. You review galley proofs before publication. Article published online with DOI assignment.
Days 74-83Average Total Time: Submission to Publication in ~60 days
Why MS Researchers Choose Us
Indexed in Major Databases
Your research gains worldwide visibility through indexing in Google Scholar, connecting it with the global scientific community.
Fast Decisions
Average time to first decision: 21 days. We respect your time and understand the urgency of advancing MS research
Expert Reviewers
Peer review by neurologists, neuroimmunologists, and MS specialists who understand the nuances of demyelinating disease research
Immediate Global Access
Open Access publishing ensures your findings reach clinicians, researchers, and patients worldwide without subscription barriers
Ethical Publishing
Committed to COPE publication ethics, transparent peer review, and rigorous standards. We handle misconduct allegations seriously and fairly.
APC Waivers Available
Financial support for authors from low-income countries and unfunded research. Quality research should not be limited by finances
Submission Guidelines & Resources
Familiarize yourself with our requirements before submission to ensure a smooth review process.
Author Guidelines
Comprehensive instructions on manuscript preparation, formatting requirements, reference style, and ethical considerations specific to MS research.
Reviewer Guidelines
Understand our peer review process and criteria. Transparency in review standards helps you prepare stronger manuscripts.
Editor Guidelines
Learn about our editorial decision-making process and the criteria editors use to evaluate MS research manuscripts.
Published Articles
Browse our archives to see the quality and scope of MS research we publish. Get inspiration for your own submission.
Frequently Asked Questions
Common questions about submission, peer review, publication fees, copyright, and open access licensing answered.
Ready to Share Your MS Research with the World?
Join researchers advancing our understanding of multiple sclerosis and improving patient outcomes. Your work deserves expert review and global visibility.
Submit Your Manuscript NowNeed assistance with your submission? Our editorial team is here to help at [email protected]
